Ascend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content
Ascend Laboratories recalls 10mg/20mg Amlodipine and Olmesartan Medoxomil tablets (NDC 67877-500-30) due to failed dissolution specs causing low drug content. Rx only, manufactured in India, distributed in US.
Lower-risk recall
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
What happened, in plain English
Ascend Laboratories is recalling certain blood pressure medication tablets because they contain less active ingredient than labeled. This could lead to ineffective treatment if taken without proper dosage. The recall applies to prescription-only tablets sold in the US. Read more at govinfonow.com/recall/92436-ascend-laboratories-recalls-amlodipine-olmesartan-tablets-with-low-drug-content.
Source Summary by GovInfoNow · govinfonow.com/recall/92436-ascend-laboratories-recalls-amlodipine-olmesartan-tablets-with-low-drug-content · Updated August 17, 2026 · FDA enforcement record: FDA #D-0712-2026
Cite this page
“Ascend Laboratories recalls Amlodipine/Olmesartan tablets with low drug content.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/92436-ascend-laboratories-recalls-amlodipine-olmesartan-tablets-with-low-drug-content. Based on FDA recall #D-0712-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0712-2026%22&limit=1).
Why it’s dangerous
The tablets failed to dissolve properly in the body, resulting in lower than expected levels of the active medication. This means the treatment might not work as intended, potentially leading to uncontrolled blood pressure. However, the risk is not immediate or life-threatening.
Who’s affected
Prescription patients who received these specific tablets from Ascend Laboratories in the US. Those with uncontrolled hypertension may be at slightly higher risk if the medication isn't working properly.
How to tell if you have this one
Check for the product name 'Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle' on the label. Look for NDC code 67877-500-30 and lot number 25121311 with expiration 3/31/2028.
- Brand
Ascend Laboratories- Category
Drug
What to do — step by step
Check Medication Label
Look for the NDC code 67877-500-30 and lot number 25121311 on the bottle.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 21 days after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Ascend Laboratories recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0712-2026 (July 8, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0712-2026 to see it in context.
- Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.